Gene therapies in the market today use viral vectors to introduce modified genetic material into targeted cells. This means gene therapy manufacturing starts with the upstream production of vectors either through transient transfection or use of stable producer cell line which culminates in the harvesting of the viral vector produced. This feeds into downstream purification and concentration to ensure the product has high efficacy and safety to pass regulatory requirements. Therefore, making the right upstream process decisions not only impacts immediate upstream outputs, but also downstream processes, timelines and regulatory acceptance.
Four major challenges that face upstream manufacturing today include: High productivity, process robustness, scalability for commercial production, and product quality. Using optimized, time-effective upstream production platforms can help gene therapy manufacturers address key upstream challenges. Draw on our experience to learn how you can speed your gene therapy to patients.
Are you looking for a platform that achieves best-in-class performance for lentivirus production?
Are you an AAV manufacturer looking for a high quality, high performance upstream platform?
Scaling up viral vector production using adherent cell culture systems is challenging. Learn how suspension cell culture systems benefit large-scale bioprocessing.
The production of AAV viral vectors for gene therapy comes with unique upstream challenges. Learn how our HEK platform can solve these challenges.
A step-by-step overview of suspension-based, transient transfection bioreactor process development and scaleup of lentivirus production.
To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.
See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.
The VirusExpress® 293T Lentiviral Production Platform offers a transfection-based solution to LV production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at 50 L scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients.
The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a HEK293 suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to commercial production. The VirusExpress® Production Platform offers a higher vector yield than adherent platforms and a simpler process than competitor products. The VirusExpress® Production Platform has been optimized for AAV2, AAV5, AAV6 and other serotype production.
The Sf-RVN® Insect Cell Line offers a rhabdovirus-free alternative and enhances risk mitigation. Together with the chemically defined medium, EX-CELL® CD Insect Cell Medium, forms the Sf-RVN® Platform, providing a high-performance platform optimal to produce adeno-associated vectors (AAV) for gene therapy applications.
To continue reading please sign in or create an account.Don't Have An Account?